Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab
ConclusionEarly CRP kinetics is associated with survival of advanced urothelial cancer patients treated with pembrolizumab and could be a potential biomarker for clinical benefit from immune checkpoint inhibitors.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Immunotherapy | Liver | Statistics | Urology & Nephrology